These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15580317)

  • 21. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study.
    Hassan W; Al-Sergani H; Al Buraiki J; Dunn B; Al Turki F; Akhras N; Elshaer F; Nawaz M; Kharabsheh S; ElKum N
    Am Heart J; 2007 Aug; 154(2):345-51. PubMed ID: 17643587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question?
    Young JJ; Kereiakes DJ
    J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
    Coto H
    J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.
    Zeymer U; Zahn R; Schiele R; Jansen W; Girth E; Gitt A; Seidl K; Schröder R; Schneider S; Senges J
    Eur Heart J; 2005 Oct; 26(19):1971-7. PubMed ID: 15857851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eptifibatide and tirofiban: new preparations. Limited benefit.
    Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
    J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant use of eptifibatide and enoxaparin in the medical management of a patient with a non-ST segment elevation acute coronary syndrome and in-stent restenosis.
    Nahlawi M; Benzuly K; Fintel D
    J Invasive Cardiol; 2000 Dec; 12 Suppl D():16D-8D. PubMed ID: 11156717
    [No Abstract]   [Full Text] [Related]  

  • 31. [Comparison of 2 platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Rossi ML; Merlini PA
    Ital Heart J Suppl; 2001 Oct; 2(10):1130-2. PubMed ID: 11723620
    [No Abstract]   [Full Text] [Related]  

  • 32. The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction.
    Lev EI; Kornowski R; Teplisky I; Hasdai D; Rechavia E; Shor N; Battler A; Assali AR
    Int J Cardiovasc Intervent; 2005; 7(1):41-5. PubMed ID: 16019614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
    Szucs TD; Schwenkglenks M; Berger K; Karsch K
    Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
    Midei MG; Coombs VJ; Lowry DR; Drossner MN; Prewitt KC; Wang JC; Loughrey MB; Gottlieb SO
    Cardiology; 2007; 107(3):172-7. PubMed ID: 16940721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose tirofiban administered as bolus-only during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Manjappa N; Cavusoglu E
    J Invasive Cardiol; 2008 Feb; 20(2):53-8. PubMed ID: 18252967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct intracoronary delivery of tirofiban during primary percutaneous coronary intervention for ST-elevation myocardial infarction.
    Shen WF
    Chin Med J (Engl); 2012 Jan; 125(1):3-6. PubMed ID: 22340456
    [No Abstract]   [Full Text] [Related]  

  • 38. Microcirculatory effects of abciximab and eptifibatide: a critical appraisal.
    Kereiakes DJ
    J Invasive Cardiol; 2003 Sep; 15(9):481-3. PubMed ID: 12947205
    [No Abstract]   [Full Text] [Related]  

  • 39. Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experience.
    Cantor WJ; Tcheng JE; Blankenship JC; O'Shea JC; Pieper KS; Criger DA; Madan M; Ducas J; Sheldon WS; Tannenbaum MA; Smith JE; Kitt MM; Gilchrist IC
    J Invasive Cardiol; 2004 Sep; 16(9):475-81. PubMed ID: 15353828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PCI with and without abciximab after upstream eptifibatide use: outcomes in high-risk patients.
    Applegate RJ; Grabarczyk MA; Sane DC; Sacrinty MT; Goodin JE; Statonk GS; Baki TT; Gandhi SK; Kutcher MA; Little WC
    J Invasive Cardiol; 2006 Dec; 18(12):604-13. PubMed ID: 17197712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.